Julie M. Roda

1.7k total citations
37 papers, 1.3k citations indexed

About

Julie M. Roda is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Julie M. Roda has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 16 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Oncology. Recurrent topics in Julie M. Roda's work include Immune Cell Function and Interaction (17 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and CAR-T cell therapy research (7 papers). Julie M. Roda is often cited by papers focused on Immune Cell Function and Interaction (17 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and CAR-T cell therapy research (7 papers). Julie M. Roda collaborates with scholars based in United States, Switzerland and Canada. Julie M. Roda's co-authors include William E. Carson, Robin Parihar, Susheela Tridandapani, Amy Lehman, Clay B. Marsh, Timothy D. Eubank, Michael A. Caligiuri, Aruna Mani, Trupti Joshi and Cynthia M. Magro and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Julie M. Roda

36 papers receiving 1.3k citations

Peers

Countries citing papers authored by Julie M. Roda

Since Specialization

Citations

This map shows the geographic impact of Julie M. Roda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie M. Roda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie M. Roda more than expected).

Fields of papers citing papers by Julie M. Roda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie M. Roda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie M. Roda. The network helps show where Julie M. Roda may publish in the future.

Co-authorship network of co-authors of Julie M. Roda

This figure shows the co-authorship network connecting the top 25 collaborators of Julie M. Roda. A scholar is included among the top collaborators of Julie M. Roda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie M. Roda. Julie M. Roda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 3641: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors 2024 ·Cancer Research ·Lisa K. Blum, (unknown), Anushka De Costa, (unknown), Geoffrey W. Stone, (unknown), Jerry Kok Yen Chan, (unknown), (unknown), Ursula Jeffry, Kefei Zhou, Joanne Sloan‐Lancaster, (unknown), Vladimir Hanes, Hsiao D. Lieu, Daniel D. Kaplan, Julie M. Roda	0
2	A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma 2023 ·Cell Reports Medicine ·Francesco Di Meo, (unknown), (unknown), Rujin Cheng, Christina Y. Yu, (unknown), Noriyoshi Kurihara, (unknown), Arafat Aljoufi, Silvia Marino, Rajesh K. Soni, Julie M. Roda, James Sissons, Ly Vu, Mónica L. Guzmán, Kun Huang, Tamara Laskowski, Hal E. Broxmeyer, David Roodman, Fabiana Perna	17
3	A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma 2022 ·Blood ·Francesco Di Meo, (unknown), (unknown), Christina Y. Yu, Rujin Cheng, (unknown), Silvia Marino, Arafat Aljoufi, Rajesh K. Soni, Julie M. Roda, James Sissons, Ly Vu, Mónica L. Guzmán, Kun Huang, David Roodman, Fabiana Perna	2
4	Abstract LB156: Preclinical evaluation of NGM707, a novel anti-ILT2/anti-ILT4 dual antagonist monoclonal antibody 2021 ·Cancer Research ·Kalyani Mondal, Christina Song, Jane Tian, (unknown), Lee B. Rivera, Jiawei Huang, Peirong Chen, Suzanne Crawley, (unknown), (unknown), Julie M. Roda, D. T. Shen, Hui Tian, Yan Wang, Alan K. Kutach, Jeong Kim, James Sissons, Daniel D. Kaplan, Geoffrey W. Stone	6
5	Hypoxia-Inducible Factor α Subunits Regulate Tie2-Expressing Macrophages That Influence Tumor Oxygen and Perfusion in Murine Breast Cancer 2020 ·The Journal of Immunology ·(unknown), (unknown), Andrey A. Bobko, (unknown), Marieta Gencheva, Julie M. Roda, Sara L. Cole, Xiaokui Mo, (unknown), Randall Evans, Amy C. Gross, Leni Moldovan, Clay B. Marsh, Valery V. Khramtsov, Timothy D. Eubank	9
6	Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory 2015 ·Cancer Research ·Minu K. Srivastava, Christopher L. Murriel, Julie M. Roda, (unknown), Fumiko Axelrod, Ming-Hong Xie, (unknown), Erin Mayes, Trevor Bentley, Belinda Cancilla, (unknown), Tracy Tang, Ann M. Kapoun, John Lewicki, Tim Hoey, Austin Gurney, (unknown)	1
7	Fcγ Receptor-induced Soluble Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Production Inhibits Angiogenesis and Enhances Efficacy of Anti-tumor Antibodies 2013 ·Journal of Biological Chemistry ·(unknown), (unknown), (unknown), Prexy Shah, Payal Mehta, Julie M. Roda, Xiaokui Mo, Carolyn Cheney, Erin Hertlein, Timothy D. Eubank, Clay B. Marsh, Natarajan Muthusamy, Jonathan P. Butchar, John C. Byrd, Susheela Tridandapani	11
8	Stabilization of HIF-2α Induces sVEGFR-1 Production from Tumor-Associated Macrophages and Decreases Tumor Growth in a Murine Melanoma Model 2012 ·The Journal of Immunology ·Julie M. Roda, (unknown), (unknown), Gary Phillips, Clay B. Marsh, Timothy D. Eubank	60
9	Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell–activating cytokines 2012 ·Surgery ·(unknown), Alena Cristina Jaime‐Ramirez, (unknown), Julie M. Roda, Moaz M. Choudhary, Bhavna Kumar, Theodoros N. Teknos, William E. Carson	49
10	Hypoxia Inducible Factors-Mediated Inhibition of Cancer by GM-CSF: A Mathematical Model 2012 ·Bulletin of Mathematical Biology ·Duan Chen, Julie M. Roda, Clay B. Marsh, Timothy D. Eubank, Avner Friedman	27
11	IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production 2011 ·The Journal of Immunology ·Alena Cristina Jaime‐Ramirez, Bethany L. Mundy-Bosse, (unknown), Natalie Jones, Julie M. Roda, Aruna Mani, Robin Parihar, Volodymyr Karpa, Tracey L. Papenfuss, Krista LaPerle, (unknown), Amy Lehman, Abhik Ray Chaudhury, David Jarjoura, Richard W. Burry, William E. Carson	81
12	Hypoxia-Inducible Factor-2α Regulates GM-CSF–Derived Soluble Vascular Endothelial Growth Factor Receptor 1 Production from Macrophages and Inhibits Tumor Growth and Angiogenesis 2011 ·The Journal of Immunology ·Julie M. Roda, (unknown), Randall Evans, Gary Phillips, Clay B. Marsh, Timothy D. Eubank	61
13	Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes 2010 ·Blood ·Timothy D. Eubank, Julie M. Roda, Haowen Liu, (unknown), Clay B. Marsh	79
14	A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab 2008 ·Breast Cancer Research and Treatment ·Aruna Mani, Julie M. Roda, Donn C. Young, Michael A. Caligiuri, Gini F. Fleming, Peter A. Kaufman, Adam Brufsky, (unknown), William E. Carson, Charles L. Shapiro	36
15	Colocalization of the IL-12 receptor and FcγRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-γ 2008 ·Blood ·Sri Vidya Kondadasula, Julie M. Roda, Robin Parihar, Jianhua Yu, Amy Lehman, Michael A. Caligiuri, Susheela Tridandapani, Richard W. Burry, William E. Carson	65
16	IL-21 Promotes Apoptosis through Induction of the BH3 Only Protein Bim and Enhacnes Direct and Innate Immune-Promoted Death of Chronic Lymphocytic Leukemia Cells. 2007 ·Blood ·Julie M. Roda, Aruna Gowda, Rehan M. Hussain, Asha Ramanunni, Amy Lehman, Wayne Kindsvogel, William E. Carson, Natarajan Muthusamy, John C. Byrd	1
17	IL-21 enhances natural killer cell activation in response to antibody-coated tumor cells 2006 ·Cancer Research ·Julie M. Roda, Robin Parihar, Susheela Tridandapani, William E. Carson	1
18	Interferon α and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects 2006 ·Surgery ·(unknown), Julie M. Roda, Catherine E. Terrell, Abhik Ray Chaudhury, (unknown), William E. Carson, Gregory B. Lesinski	10
19	Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets 2006 ·The Journal of Immunology ·Julie M. Roda, Robin Parihar, Amy Lehman, Aruna Mani, Susheela Tridandapani, William E. Carson	100
20	CpG-Containing Oligodeoxynucleotides Act through TLR9 to Enhance the NK Cell Cytokine Response to Antibody-Coated Tumor Cells 2005 ·The Journal of Immunology ·Julie M. Roda, Robin Parihar, William E. Carson	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact